Alpha 2.0
Login Register
» Authors » Saijuan Zhang

Saijuan Zhang

Explore the profile of Saijuan Zhang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 150
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
General Medicine
Top 10 Co-Authors
S Aubrey Stoch
Marian Iwamoto
Deanne Jackson Rudd
Randolph P Matthews
Jay A Grobler
Kerry L Fillgrove
Raymond J Carroll
Victor Kipnis
Douglas Midthune
Andrea Schaeffer
Published In
J Acquir Immune Defic Syndr
J Clin Pharmacol
Ann Appl Stat
Lancet HIV
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
Ankrom W, Jackson Rudd D, Zhang S, Fillgrove K, Gravesande K, Matthews R, et al.
J Int AIDS Soc . 2021 Dec; 24(12):e25858. PMID: 34935295
Introduction: Hormonal contraceptives are among the most effective forms of reversible contraception, but many other compounds, including some antiretrovirals, have clinically meaningful drug-drug interactions (DDIs) with hormonal contraceptives. Islatravir is...
2.
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
Jackson Rudd D, Zhang S, Fillgrove K, Fox-Bosetti S, Matthews R, Friedman E, et al.
Clin Pharmacol Drug Dev . 2021 Oct; 10(12):1432-1441. PMID: 34676683
Islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, is in clinical development for the treatment and prevention of HIV-1 infection. Because islatravir may be coadministered with other antiretroviral agents, assessment...
3.
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week
Schurmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman E, Robberechts M, et al.
J Acquir Immune Defic Syndr . 2021 Oct; 89(2):191-198. PMID: 34654041
Background: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support...
4.
Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV
Matthews R, Jackson Rudd D, Zhang S, Fillgrove K, Sterling L, Grobler J, et al.
J Acquir Immune Defic Syndr . 2021 Oct; 88(3):314-321. PMID: 34651606
Background: Islatravir (MK-8591) is a novel nucleoside analog in development for the treatment and prevention of HIV-1 infection. Islatravir has potent antiviral activity and a long intracellular half-life. Setting: A...
5.
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial
Matthews R, Patel M, Barrett S, Haspeslagh L, Reynders T, Zhang S, et al.
Nat Med . 2021 Oct; 27(10):1712-1717. PMID: 34608329
Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that is in development for the prevention and...
6.
Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor
Gillespie G, Jackson Rudd D, Zhang S, Schaeffer A, Tomek C, Larson P, et al.
J Clin Pharmacol . 2021 Aug; 62(2):199-205. PMID: 34435371
MK-8507 is an investigational HIV-1 nonnucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1 infection. MK-8507 contains 2 trifluoromethyl groups that may result in fluoride release through metabolism,...
7.
A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants
Gillespie G, Jackson Rudd D, Zhang S, Schaeffer A, Tomek C, Larson P, et al.
J Clin Pharmacol . 2021 Aug; 62(2):190-198. PMID: 34432899
Chronic overexposure to fluoride can have deleterious effects in the musculoskeletal system. Some fluorine-containing therapeutics, such as voriconazole, release fluoride through metabolism. Therefore, drug-related fluoride exposure should be assessed for...
8.
A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
Matthews R, Jackson Rudd D, Fillgrove K, Zhang S, Tomek C, Stoch S, et al.
Clin Drug Investig . 2021 Jun; 41(7):629-638. PMID: 34151413
Background And Objectives: Islatravir (MK-8591) is a novel nucleoside analogue in development for the treatment and prevention of HIV-1 infection. Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the...
9.
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label,...
Schurmann D, Jackson Rudd D, Zhang S, De Lepeleire I, Robberechts M, Friedman E, et al.
Lancet HIV . 2020 Jan; 7(3):e164-e172. PMID: 31911147
Background: Islatravir (also known as ISL and MK-8591) is a unique nucleoside reverse transcriptase translocation inhibitor in clinical development for treatment of people with HIV-1 infection. In preclinical studies, intracellular...
10.
Fitting a bivariate measurement error model for episodically consumed dietary components
Zhang S, Krebs-Smith S, Midthune D, Perez A, Buckman D, Kipnis V, et al.
Int J Biostat . 2012 Aug; 7(1):1. PMID: 22848190
There has been great public health interest in estimating usual, i.e., long-term average, intake of episodically consumed dietary components that are not consumed daily by everyone, e.g., fish, red meat...